The Biologics Prescribers Collaborative appreciates FDA’s careful consideration before approving biosimilar applicants. As of December 2018, there are 16 approved biosimilars, with additional approvals expected in the future. This index outlines several key components of biosimilars, including:
- Proprietary drug name
- Reference biologic and manufacture
- Approved indications